Department of Medical Oncology, Curie Institute, Paris, France.
Division of Cancer Medicine, Gustave Roussy, Villejuif, France.
Cancer Med. 2023 Feb;12(3):3160-3166. doi: 10.1002/cam4.5147. Epub 2022 Aug 15.
Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single-agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI-CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1-6.5), and median OS was 9.9 months (95%CI: 6.6-13.4). Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.
吉西他滨在小系列中单独或与紫杉烷联合治疗血管肉瘤显示出临床活性。我们旨在评估其在更大系列晚期血管肉瘤患者中的单药活性。我们回顾性地审查了我们机构 2010 年 1 月至 2021 年 1 月期间接受单药吉西他滨治疗的连续成人晚期血管肉瘤患者的电子病历。根据 RECIST 1.1 评估反应，根据 NCI-CTC v5.0 分级毒性。确定了 42 名患者。38 名患者（90%）接受过蒽环类药物和每周紫杉醇治疗，9 名患者（21%）接受过帕唑帕尼治疗。16 名患者（38%）的最佳肿瘤反应为部分缓解（PR）或稳定疾病（10 名患者，24%）。所有 8 名心脏血管肉瘤患者均经历 PR。中位 PFS 为 5.4 个月（95%CI：3.1-6.5），中位 OS 为 9.9 个月（95%CI：6.6-13.4）。单药吉西他滨在晚期、大量预处理的血管肉瘤中具有临床意义的活性。
